Track topics on Twitter Track topics that are important to you
Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses the most advanced technology to supply physicians with a novel diagnostic tool and thereby provide patients with personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.
Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.
Abionic SA is a privately held high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab. The company also benefits from coaching of Genilem, the A3 Angels mentoring program and the CTI coaching.
Abionic was founded in 2010 by former scientists of the biomedical optics laboratory (LOB) at EPFL. The headquarters are located in Lausanne, Switzerland.
c/o EPFL - STI - LOB - BM4247
Phone: +41 79 753 57 66
Fax: +41 21 693 78 20
Abionic, a Swiss diagnostics firm, has developed an assay that is capable of predicting within a 5-minute period which patien -More-
In the U.S., 25 million people suffer from asthma, the majority of which have allergic asthma. Allergic asthma can be life threatening. This makes access to prompt, accurate diagnosis and appropri...
Abionic SA, Swiss Medtech firm based in Lausanne, is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first tria...
A breakthrough on sepsis diagnosis on today’s World Sepsis Day Every 3 seconds someone dies of sepsis globally. Sepsis is #1 killer at hospitals, it claims more lives than prostate cancer, breas...
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE devi...
Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abi...
Abionic has developed and commercialized abioSCOPE, a rapid point of care diagnostic platform to improve medical diagnosis. This revolutionary nano-technology-based test system pr...
We have published hundreds of Abionic news stories on BioPortfolio along with dozens of Abionic Clinical Trials and PubMed Articles about Abionic for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Abionic Companies in our database. You can also find out about relevant Abionic Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Nanotechnology is the engineering of functional systems at the molecular scale. This covers both current work and concepts that are more advanced. In its original sense, 'nanotechnology' refers to the projected ability to construct items fr...
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...